Beaten by placebo, Evelo seeks partner for once-lauded microbiome platform and programs

Evelo Biosciences’ last roll of the dice has come up snake eyes. After seeing its lead candidate flounder in the clinic, the biotech has revealed its next-generation asset performed worse than placebo in a phase 2 psoriasis trial, prompting it to start searching for strategic alternatives.